Radin M J, Wilke W L, Fettman M J
Department of Pathology, Colorado State University, Fort Collins 80523.
Proc Soc Exp Biol Med. 1989 Mar;190(3):294-300. doi: 10.3181/00379727-190-42863.
The effect of varying doses of captopril, an angiotensin I-converting enzyme inhibitor, on renal hemodynamics, systemic arterial pressure, and the progression of chronic renal disease in conscious, three-quarter nephrectomized adult male Sprague-Dawley rats was studied. Six weeks following nephrectomy (Week 0), rats were randomly divided into five groups. Group 2 (n = 8), 3 (n = 8), 4 (n = 9), and 5 (n = 5) were given 5, 10, 20, and 40 mg/kg captopril, respectively, daily in drinking water. Group 1 (n = 7) and sham-operated controls (n = 7) were given water only. On Weeks -6, 0, 2, and 4, renal function was assessed by 24-hr urinary protein excretion and plasma creatinine. Systolic blood pressure was measured at these times by the tail cuff method. Following Week 4, glomerular filtration rate and effective renal plasma flow were measured in conscious rats by single injection clearance of [3H]inulin and [14C]tetraethylammonium bromide, respectively. Group 1 had significantly higher (P less than 0.05) 24-h urinary protein excretion, plasma creatinine, and systolic pressure compared with Group 5 and controls by Week 4, whereas values for these parameters for Groups 2-4 ranged between these extremes. Although systolic pressures were not significantly different (P greater than 0.05), Group 2 had significantly lower proteinuria than Group 1 (P less than 0.05) at Week 4. Total kidney glomerular filtration rate was similarly decreased in Groups 1-5 compared with control rats. Total kidney effective renal plasma flow was higher in captopril-treated groups than in Group 1, whereas systolic blood pressure was similar or lower, indicating that captopril reduced renal vascular resistance. Furthermore, unlike Groups 1-3, the groups receiving higher doses of captopril (4 and 5) did not develop anemia associated with chronic renal disease. In conclusion, captopril attenuated renal functional deterioration in a dose-related manner. The effect on proteinuria was evident at low doses of captopril which did not significantly reduce systemic blood pressure and was accompanied by an increase in effective renal plasma flow and a decrease in renal vascular resistance.
研究了血管紧张素I转换酶抑制剂卡托普利不同剂量对清醒的、切除四分之三肾的成年雄性Sprague-Dawley大鼠的肾血流动力学、体动脉血压和慢性肾病进展的影响。肾切除术后六周(第0周),将大鼠随机分为五组。第2组(n = 8)、第3组(n = 8)、第4组(n = 9)和第5组(n = 5)分别通过饮用水每日给予5、10、20和40 mg/kg卡托普利。第1组(n = 7)和假手术对照组(n = 7)仅给予水。在第-6、0、2和4周,通过24小时尿蛋白排泄和血浆肌酐评估肾功能。在这些时间通过尾袖法测量收缩压。第4周后,分别通过单次注射[3H]菊粉和[14C]四乙基溴化铵清除率在清醒大鼠中测量肾小球滤过率和有效肾血浆流量。到第4周时,与第5组和对照组相比,第1组的24小时尿蛋白排泄、血浆肌酐和收缩压显著更高(P <0.05),而第2 - 4组这些参数的值介于这两个极端值之间。尽管收缩压无显著差异(P>0.05),但在第4周时第2组的蛋白尿显著低于第1组(P <0.05)。与对照大鼠相比,第1 - 5组的总肾肾小球滤过率同样降低。卡托普利治疗组的总肾有效肾血浆流量高于第1组,而收缩压相似或更低,表明卡托普利降低了肾血管阻力。此外,与第1 - 3组不同,接受较高剂量卡托普利(第4和5组)的组未发生与慢性肾病相关的贫血。总之,卡托普利以剂量相关的方式减轻了肾功能恶化。低剂量卡托普利对蛋白尿的影响明显,此时并未显著降低体循环血压,且伴有有效肾血浆流量增加和肾血管阻力降低。